

CITATION REPORT

List of articles citing

Cost to Medicare of Delayed Adalimumab Biosimilar Availability

DOI: 10.1002/cpt.2322
Clinical Pharmacology and Therapeutics, 2021, 110, 1050-1059

Source: <https://exaly.com/paper-pdf/81564128/citation-report.pdf>
Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Lost Medicare savings due to delayed adalimumab biosimilar marketing. <i>PharmacoEconomics & Outcomes News</i> , 2021 , 882, 18-18	0.1	
7	Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. <i>Health Affairs</i> , 2021 , 40, 1198-1205	7	6
6	A review of biosimilars for rheumatoid arthritis.. <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102234	5.1	0
5	A Historical Review of Brain Drug Delivery. <i>Pharmaceutics</i> , 2022 , 14, 1283	6.4	5
4	Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial. <i>Clinical Rheumatology</i> ,	3.9	
3	Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study. 9,		0
2	An Institutional Guide for Formulary Decisions of Biosimilars. 001857872211380		1
1	Consistency of Product Quality for SB5, an Adalimumab Biosimilar.		0